MSI tumors are characterized by a high tumor mutational burden (TMB) and elevated neoantigen load, which promote robust T cell infiltration and increased responsiveness to PD-1/PD-L1 immune checkpoint blockade [75]. This evidence concerns the gene CD274 and neoplasm.